Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

Author： Maira Sauveur-Michel Voliva Charles Garcia-Echeverria Carlos

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.12, Iss.2, 2008-02, pp. : 223-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3057-3069

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets

Current Drug Targets, Vol. 12, Iss. 7, 2011-06 ,pp. : 1056-1081

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of phosphatidylinositol 3-kinase

By Zahradka P.

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 97-99

Informa Healthcare

Access to resources Recommend Favorite

Designing in vitro assays for drug discovery: a study with the human MAP3 kinase COT

By Jia Yong Quinn Christopher M Talanian Robert V

Expert Opinion on Drug Discovery, Vol. 2, Iss. 7, 2007-07 ,pp. : 909-915

Informa Healthcare

Access to resources Recommend Favorite

Kinase Chemogenomics: Targeting the Human Kinome for Target Validation and Drug Discovery

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 235-253

Bentham Science Publishers

Access to resources Recommend Favorite